
SELLAS Life Sciences: Phase 3 AML Trial Meets Survival Endpoint; Plans FDA Meeting
SELLAS Life Sciences Group announced positive topline results from its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML). The trial met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement with a 41% reduction in the risk of death (hazard ratio of 0.59, p=0.035) and a median OS of 24.0 months compared to 14.7 months for best available treatment. GPS was well-tolerated with no new safety signals. The company plans to meet with the FDA to discuss an accelerated filing strategy and prepare for a Biologics License Application (BLA) submission.
Key Highlights
- SELLAS Life Sciences Group announces positive topline results from Phase 3 REGAL trial for galinpepimut-S (GPS) in AML patients.
- The trial met its primary endpoint of overall survival (OS), showing a 41% reduction in risk of death (HR 0.59, p=0.035).
- Median OS was 24.0 months for GPS-treated patients versus 14.7 months for best available treatment (BAT).
- GPS demonstrated a statistically significant and clinically meaningful improvement in OS compared to BAT.
- GPS was generally well tolerated with a safety profile consistent with prior clinical experience and no new safety signals.
- Company plans to meet with the FDA to discuss an accelerated filing strategy and advance preparations for a BLA submission for GPS.
Price Impact
More from SLS